LYON, France–( BUSINESS WIRE )–POXEL S.A. (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it plans to conduct a registered initial public offering in the United States. The timing, number of securities and price of […]
Poxel, which is based out of Lyon, France, is an innovative biopharmaceutical company. The company specializes in the development of drugs to treat metabolic diseases. Most notably, Poxel focuses on the development of new type 2 diabetes medications. Their leading compound, Imeglimin, has completed Phase 2 clinical development in the United States and Europe. The compound achieved proof-of-concept in 2 Phase 2a trials and manages to achieve primary and secondary endpoints, during a Phase 2b dose-ranging trial.
The company, which originated in 2009, currently employs 18 people. The company’s stock began trading on the Euronext Paris exchange on February 6, 2016 under the POXEL ticker. The stock’s IPO price was set was EUR 6.66. It has a 1 year high of 16.75 and closed the day’s trading at 13.72. Those looking for more information about Poxel should visit their website.
